EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Changes in NK Cells and Exhausted Th Cell Phenotype in RA Patients Treated with Janus Kinase Inhibitors: Implications for Adverse Effects

Juan José Fernández-Cabero iD, Carmen Lasa-Teja iD, David San Segundo iD, Alejandra Comins-Boo iD, Juan Irure-Ventura iD, David Walias Rivera, Jose Luis Martín-Varillas, Cristina Mata, Montserrat Santos, Elena Aurrecoechea iD, Ricardo Blanco iD, Marcos López-Hoyos iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26115160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Juan José Fernández-Cabero und 11 weiteren Autor:innen. Beteiligte Einrichtung: Immunopathology Group, Instituto de Investigación Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Killer Cells, Natural, Janus Kinase Inhibitors, T-Lymphocytes, Helper-Inducer. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline (Spain), GSK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent concerns regarding the safety of Janus kinase inhibitors (JAKis) have prompted investigation into their impact on immune cell subsets in rheumatoid arthritis (RA) patients. This study aims to analyse alterations in immune cell populations induced by JAKis that may contribute to adverse events, such as infections or malignancies. This study included 78 RA patients meeting ACR/EULAR criteria with an established treatment with JAKis (tofacitinib, baricitinib, upadacitinib, or filgotinib), 20 healthy donors, and 20 RA patients treated with biological disease-modifying antirheumatic drugs (bDMARDs). Peripheral blood mononuclear cells (PBMCs) were immunophenotyped directly after isolation using multiparametric flow cytometry to characterise innate and adaptive immune-cell subsets. JAKi-treated patients showed a significant reduction in cytotoxic NK Dim (CD3−CD56+CD16+) cells and in the percentage of NK Dim cells expressing the activation marker Nkp30. In CD4+ T cells, the percentage of Th17 (CD3+CD4+CD45RA+CCR6+CXCR3−), Th1-17 (CD3+CD4+CD45RA+CCR6+CXCR3+), and central memory (CM, CD3+CD4+CD45RA+CD62L+) cells was lower in the JAKi group, while effector memory (EM, CD3+CD4+CD45RA−CD62L−) and terminally differentiated CD45RA (TEMRA, CD3+CD4+CD45RA+CD62L−) T helper cells were increased compared to healthy and bDMARD-treated controls. The reduction in NK Dim and Th1-17 cells and the increase in exhausted Th subsets suggest a potential compromise in antiviral immunity and balanced immune responses in JAKi-treated RA patients. These alterations may contribute to an increased risk of infections or malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidKiller Cells, NaturalJanus Kinase InhibitorsT-Lymphocytes, Helper-InducerHumansMiddle AgedFemaleMaleAdultAgedImmunophenotypingAzetidinesPiperidinesPhenotypePyrimidinesPyrazolesAntirheumatic AgentsPurinesSulfonamides

Stichwörter der Autor:innen

JAKiNK cellsTh cellsflow cytometrymonocytesrheumatoid arthritis

Substanzen

Janus Kinase InhibitorsAzetidinesPiperidinesPyrimidinesPyrazolesAntirheumatic AgentstofacitinibbaricitinibPurinesSulfonamides

Autor:innen und Institutionen

  • Immunopathology Group, Instituto de Investigación Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.
  • Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.
  • Department of Immunology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.
  • Cantabria Tissue and Blood Bank, Fundación Marqués de Valdecilla, 39008 Santander, Spain.
  • Department of Rheumatology, Hospital de Laredo, 39770 Laredo, Spain.
  • Department of Rheumatology, Hospital Sierrallana, 39300 Torrelavega, Spain.

ORCID-Profile: Juan José Fernández-Cabero, Carmen Lasa-Teja, David San Segundo, Alejandra Comins-Boo, Juan Irure-Ventura, Elena Aurrecoechea, Ricardo Blanco, Marcos López-Hoyos

Förderung

  • GlaxoSmithKline (Spain)
  • GSK

Zitieren

APA

Fernández-Cabero, J. J., Lasa-Teja, C., San Segundo, D., Comins-Boo, A., Irure-Ventura, J., Walias Rivera, D., Martín-Varillas, J. L., Mata, C., Santos, M., Aurrecoechea, E., Blanco, R., & López-Hoyos, M. (2025). Changes in NK Cells and Exhausted Th Cell Phenotype in RA Patients Treated with Janus Kinase Inhibitors: Implications for Adverse Effects. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26115160

Vancouver

Fernández-Cabero JJ, Lasa-Teja C, San Segundo D, Comins-Boo A, Irure-Ventura J, Walias Rivera D, et al. Changes in NK Cells and Exhausted Th Cell Phenotype in RA Patients Treated with Janus Kinase Inhibitors: Implications for Adverse Effects. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26115160

BibTeX
@article{FernndezCabero2025,
  author = {Fernández-Cabero, Juan José and Lasa-Teja, Carmen and San Segundo, David and Comins-Boo, Alejandra and Irure-Ventura, Juan and Walias Rivera, David and Martín-Varillas, Jose Luis and Mata, Cristina and Santos, Montserrat and Aurrecoechea, Elena and Blanco, Ricardo and López-Hoyos, Marcos},
  title = {Changes in NK Cells and Exhausted Th Cell Phenotype in RA Patients Treated with Janus Kinase Inhibitors: Implications for Adverse Effects},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26115160}
}
Kostenlos starten →